论文部分内容阅读
目的探讨分析低剂量干扰素联合利巴韦林治疗丙肝代偿期肝硬化的临床疗效及安全性.方法选取2013年1月-2014年1月本院收治的丙肝代偿期肝硬化患者120例.随机分成对照组和观察组.对照组:单纯给予利巴韦林治疗;观察组:利巴韦林+低剂量干扰素联合用药治疗.对比分析两组患者的临床疗效及不良反应发生情况.结果经相应治疗后,观察组患者的病毒学指标.肝功能指标、生化指标均明显改善.且改善情况明显优于对照组.两组数据差异显著,具有统计学意义(P<0.05).两组患者并发症发生情况之间并无显著差异.结论低剂量干扰素联合利巴韦林治疗丙肝代偿期肝硬化临床效果确切.安全性高.值得临床广泛推广。
Objective To investigate the clinical efficacy and safety of low-dose interferon combined with ribavirin in the treatment of decompensated cirrhosis of hepatitis C. Methods From January 2013 to January 2014, 120 patients with decompensated cirrhosis of hepatitis C .All patients were randomly divided into control group and observation group.Control group: Ribavirin alone.Observation group: Ribavirin combined with low-dose interferon.Comparison of two groups of patients with clinical efficacy and adverse reactions. Results After corresponding treatment, the virological indexes of the patients in the observation group were significantly improved, the indexes of liver function and biochemical indexes were significantly improved, and the improvement was obviously better than that of the control group. There was significant difference between the two groups (P <0.05). There was no significant difference in the complication between the two groups.Conclusion Low-dose interferon combined with ribavirin has definite effect on hepatitis C decompensated cirrhosis and its safety is high.